Needham Reiterates Buy on Cidara Therapeutics, Maintains $3 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a price target of $3.
August 04, 2023 | 3:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Cidara Therapeutics and maintained a price target of $3.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $3 price target indicates a positive outlook for Cidara Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100